Ontology highlight
ABSTRACT:
SUBMITTER: Nixon NA
PROVIDER: S-EPMC6001768 | biostudies-literature | 2018 Jun
REPOSITORIES: biostudies-literature
Nixon N A NA Hannouf M B MB Verma S S
Current oncology (Toronto, Ont.) 20180613 Suppl 1
Cancer therapy has evolved significantly with increased adoption of biologic agents ("biologics"). That evolution is especially true for her2 (human epidermal growth factor receptor-2)-positive breast cancer with the introduction of trastuzumab, a monoclonal antibody against the her2 receptor, which, in combination with chemotherapy, significantly improves survival in both metastatic and early disease. Although the efficacy of biologics is undeniable, their expense is a significant contributor t ...[more]